Identification of VRK1 as a Novel Potential Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Vaccinia-related kinase 1 (VRK1) is highly expressed in hepatocellular carcinoma (HCC), correlating with poor prognosis and a positive response to anti-PD-L1 immunotherapy, suggesting its potential as a biomarker.
Area Of Science
- Oncology
- Molecular Biology
- Immunotherapy
Background
- Vaccinia-related kinase 1 (VRK1) is recognized for its role in the tumor cell cycle.
- The prognostic and immunotherapeutic predictive value of VRK1 in hepatocellular carcinoma (HCC) remains underexplored.
Purpose Of The Study
- To investigate the expression of VRK1 in HCC.
- To evaluate the prognostic significance of VRK1 in HCC patients.
- To determine the predictive value of VRK1 for immunotherapy response in HCC.
Main Methods
- Analysis of VRK1 expression using TCGA, ICGC, and GSE14520 datasets.
- Validation of VRK1 expression via qRT-PCR and immunohistochemistry (IHC).
- Assessment of immunotherapeutic response using the IMvigor210 cohort.
- Correlation studies on immune infiltration, m6A modification, and functional enrichment.
Main Results
- VRK1 mRNA and protein levels are significantly elevated in HCC.
- High VRK1 expression is associated with poor prognosis in HCC patients.
- Increased VRK1 expression positively correlates with response rates to anti-PD-L1 immunotherapy.
- VRK1 is linked to m6A-related genes, immune cell infiltration, and key biological processes like DNA replication and cell cycle control.
Conclusions
- VRK1 serves as a potential novel biomarker for predicting prognosis in HCC.
- VRK1 may also predict immunotherapy response in HCC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.